Publications 2013

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlinertisch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens J, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T, on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Annals of Oncology
1-7, 2013

Download publication


Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)

Steger G, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann B, Bartsch R, Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer A, Singer C, Muss C, Jakesz R, Gampenrieder S, Zielinski C, Fesl C, Gnant M on behalf of the Austrian Breast and Colorectal Study Group (ABCSG)

Annals of Oncology
1-6, 2013

Download publication


Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M and Dandachi N

Modern Pathology (2013)
1-10

Download publication


Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer

Pfeiler G, Königsberg R, Hadji P, Fitzal F, Maroske M, Dressel-Ban G, Zellinger J, Exner R, Seifert M, Singer C, Gnant M, Dubsky P

British Journal of Cancer (2013)
109:1522-1527

Download publication


The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial

Gnant M, Pfeiler G, Stöger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, Steger G, Samonigg H, Fesl C, Jakesz R on behalf of the Austrian Breast and Colorectal Cancer Study Group

British Journal of Cancer (2013)
109:589-596

Download publication


Preparing for Prospective Clinical Trials: A National Initiative of an Excellence Registry for Consecutive Pancreatic Cancer Resections

Gangl O, Sahora K, Kornprat P, Margreiter C, Primavesi F, Bareck E, Schindl M, Längle F, Öfner D, Mischinger H-J, Pratschke J, Gnant M, Függer R

World Journal of Surgery
World J Surg (2013):37

Download publication


The EndoPredict score provides prognostic information on late distant metastases in ERþ/HER2 breast cancer patients

Dubsky P, Brase J C, Jakesz R, Rudas M, Singer C F, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann M C, Petry C, Weber K E, Fisch K, Kronenwett R, Gnant M, Filipits M on behalf of the Austrian Breast and Colorectal Cancer

British Journal of Cancer (2013)
Advance online publication 24 October 2013

Download publication


Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer

Rugani P, Luschin G, Jakse N, Kirnbauer B, Lang U, Acham S

Show Abstract

Abstract

Objectives

The definite incidence rate of bisphosphonate-related osteonecrosis of the jaws (BRONJ) is still unknown. The aim of this study was to investigate prevalence of BRONJ in a group of breast cancer patients applying the classification of the Association of Oral and Maxillofacial Surgeons 2009.

Patients and methods

Between 2000 and 2008, 63 premenopausal early breast cancer patients who were free of metastases were treated with 4 mg zoledronic acid every 6 months over 3 years as participants of a multicenter, randomized, controlled, adjuvant breast cancer medication trial. Patients were not informed about the risk of jaw necrosis. None reported tooth or jaw complaints during the breast cancer follow-up examinations. In 2010, 48 patients of this cohort were investigated concerning BRONJ by clinical and radiological examinations.

Results

No advanced stages (AAOMS 2009)were detected. However, five patients (10.4 %) presented purulent (2) and nonpurulent (3) fistulas and radiological signs correlating to BRONJ stage 0.

Conclusion

Although no case of advanced BRONJ was detected, the study revealed a high prevalence of BRONJ stage 0. This supports the need for tight cooperation between dentists and medical specialists prescribing bisphosphonates including dental pre-therapeutic and follow-up examinations. Adaption of the BRONJ classification taking account to bone exposure via fistulas is recommended.

Clinical relevance

BRONJ is said to be a complication linked to high-dosage bisphosphonate therapy. The study demonstrates that even after application of zoledronate in a low-dose protocol, early BRONJ occurred. Radiological signs solely are not sufficient to confirm BRONJ; clinical signs are mandatory.

[collapse]

Clin Oral Invest 2013, June 10

Download publication


Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial

Pfeiler G, Stöger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger G, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil R, Fesl C, Gnant M

British Journal of Cancer (2013)
108:1408–1414

Download publication


CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN

Clin Cancer Res 2013;19:500-507

Download publication